Return to Health & Medicine Alert Section
New findings reported from Hartford Hospital describe advances in acute lymphoblastic leukemia
November 26th, 2007
2007 NOV 26 -- "Flow cytometric immunophenotyping (FCI) is an important diagnostic modality in the evaluation of patients who have suspected or known acute lymphoblastic leukemia (ALL). It enables rapid identification, quantification, and immunophenotypic characterization of leukemic blasts, permitting accurate and timely diagnosis," researchers in Ishikari, Japan report. "Beyond facilitating the classification of ALL into fundamental diagnostic categories, FCI may anticipate recurrent cytogenetic and molecular abnormalities. FCI permits the detection of leukemic blasts after therapy at a level lower than that achievable by conventional microscopic examination," wrote J.A. Digiuseppe and colleagues, Hartford Hospital. The researchers concluded: "Flow cytometric detection of minimal residual disease is among the strongest prognostic factors in patients who have ALL and may provide an opportunity for more precise risk-adapted therapies." Digiuseppe and colleagues published their study in Clinics in Laboratory Medicine (Acute lymphoblastic leukemia: Diagnosis and detection of minimal residual disease following therapy. Clinics in Laboratory Medicine, 2007;27(3):533+). For additional information, contact J.A. Digiuseppe, Hartford Hospital, Dept. of Pathology & Laboratory Medical, Special Hematology Laboratory, 80 Seymour St., Ishikari, Hokkaido 06102, Japan. Publisher contact information for the journal Clinics in Laboratory Medicine is: W B Saunders Co-Elsevier Inc., 1600 John F Kennedy Boulevard, Ste. 1800, Philadelphia, PA 19103-2899, USA. Keywords: Japan, Ishikari, Acute Lymphoblastic Leukemia, Hematology, Oncology, Hartford Hospital. This article was prepared by Hematology Week editors from staff and other reports. Copyright 2007, Hematology Week via NewsRx.com.
Return to Health & Medicine Alert Section
|
